Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes

Journal of Clinical Microbiology

Volumn 49, Issue 10, 2011, Pages 3474-3481

  Estrade, C ^a   Menoud, P A ^b   Nardelli Haefliger, D ^a   Sahli, R ^a,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b MCL Medical Laboratories   (Switzerland)

^c Unilabs   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; CONTROLLED STUDY; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA MICROARRAY; DNA SEQUENCE; FEMALE; GENETIC VARIABILITY; GENOTYPE; GOLD STANDARD; GOOD LABORATORY PRACTICE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PGMY POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECYCLING; REPEAT PROCEDURE; REVERSE BLOTTING HYBRIDIZATION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS TYPING; WART VIRUS;

ADULT; CLINICAL LABORATORY TECHNIQUES; FEMALE; GENOTYPE; HUMANS; MEMBRANES; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 80053513278     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05039-11     Document Type: Article

References (38)

1. Altschul, S. F., W. Gish, W. M. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.
2. Berkhof, J., et al. 2006. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol. Biomarkers Prev. 15:1268-1273. (Pubitemid 44125280)
3. Castle, P. E., P. E. Gravitt, D. Solomon, C. M. Wheeler, and M. Schiffman. 2008. A comparison of linear array and line blot assay for detection of HPV and cervical precancer and cancer in the ASCUS LSIL triage study. J. Clin. Microbiol. 46:109-117.
4. Castle, P. E., et al. 2008. A comparison of two PCR-based human papillomavirus genotyping methods. J. Clin. Microbiol. 46:3437-3445.
5. Castle, P. E., M. Sadorra, F. Garcia, E. B. Holladay, and J. Kornegay. 2006. A Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology. J. Clin. Microbiol. 44:3915-3917. (Pubitemid 44737228)
6. Clavel, C., et al. 2001. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer 84:1616-1623. (Pubitemid 32612492)
7. Clifford, G. M., J. S. Smith, M. Plummer, N. Munoz, and S. Franceschi. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88:63-73.
8. Cogliano, V., et al. 2005. Carcinogenicity of human papillomaviruses. Lancet Oncol. 6:204. (Pubitemid 40450709)
9. Coupe, V. M., et al. 2009. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int. J. Cancer 124:970-978.
10. Coutlée, F., et al. 2007. Confirmatory real-time PCR assay for HPV-52 infection in anogenital specimens screened for HPV infection with the Linear array HPV genotyping test. J. Clin. Microbiol. 45:3821-3823. (Pubitemid 350156895)
11. Coutlée, F., et al. 2006. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. J. Clin. Microbiol. 44:1998-2006. (Pubitemid 43902145)
12. Cuzick, J., et al. 1999. HPV testing in primary screening of older women. Br. J. Cancer 81:554-558. (Pubitemid 29458814)
13. Dillner, J. 2011. Technical report of the 2010 WHO HPV LabNet proficiency study on HPV testing and typing. WHO HPV LabNet Global Reference Laboratory, Malmö, Sweden.
14. Dillner, J., M. Arbyn, and L. Dillner. 2007. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin. Exp. Immunol. 148:199-207. (Pubitemid 46591311)
15. Eklund, C., T. Zhou, and J. Dillner. 2010. A global proficiency study of human papillomavirus genotyping. J. Clin. Microbiol. 48:4147-4155.
16. Ferguson, M., D. E. Wilkinson, and T. Zhou. 2009. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 27:337-347.
17. Gravitt, P. E., et al. 2000. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38:357-361. (Pubitemid 30043317)
18. Herrero, R., et al. 2005. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J. Infect. Dis. 191:1796-1807. (Pubitemid 40705385)
19. Hiller, T., S. Poppelreuther, F. Stubenrauch, and T. Iftner. 2006. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol. Biomarkers Prev. 15:1262-1267. (Pubitemid 44125279)
20. Hwang, H. S., M. Park, S. Y. Lee, K. H. Kwon, and M. G. Pang. 2004. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 Korean women determined by DNA chip. Cancer Epidemiol. Biomarkers Prev. 13:2153-2156. (Pubitemid 40054311)
21. Kjaer, S. K., et al. 2009. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. 2:868-878.
22. Kleter, B., et al. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37:2508-2517. (Pubitemid 29337270)
23. Meijer, C. J., et al. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520.
24. Muñoz, N., et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527. (Pubitemid 36159887)
25. Munoz, N., X. Castellsague, A. B. De Gonzalez, and L. Gissmann. 2006. Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl. 3):S1-S10. (Pubitemid 44293019)
26. Naucler, P., et al. 2007. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br. J. Cancer 97:129-132. (Pubitemid 47012098)
27. Paavonen, J., et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
28. Safaeian, M., et al. 2007. Comparison of the SPF10/LiPA system to the HC2 assay for detection of carcinogenic HPV genotypes among 5683 young women in Guanacaste, Costa Rica. J. Clin. Microbiol. 45:1447-1454. (Pubitemid 46762397)
29. Schiffman, M., et al. 2005. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J. Natl. Cancer Inst. 97:147-150. (Pubitemid 40277095)
30. Stanley, M., and L. L. Villa. 2008. Monitoring HPV vaccination. Vaccine 26(Suppl. 1):A24-A27. (Pubitemid 351312310)
31. Steinau, M., D. C. Swan, and E. R. Unger. 2008. Type-specific reproducibility of the Roche linear array HPV genotyping test. J. Clin. Virol. 42:412-414.
32. Szarewski, A., et al. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17:3033-3042.
33. Unger, E. R., J. Dillner, and T. Zhou (ed.). 2009. Human papillomavirus laboratory manual, 1st ed. WHO, Geneva, Switzerland.
34. Van den Brule, A. J., et al. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40:779-787. (Pubitemid 34208623)
35. Van Hamont, D., M. A. Van Ham, J. M. Bakkers, L. F. Massuger, and W. J. Melchers. 2006. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J. Clin. Microbiol. 44:3122-3129. (Pubitemid 44413740)
36. Wheeler, C. M., et al. 1996. Short-term fluctuations in the detection of cervical human papillomavirus DNA. Obstet. Gynecol. 88:261-268. (Pubitemid 26250303)
37. Wheeler, C. M., et al. 2009. The impact of quadrivalent human papillomavirus (HPV types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 199:936-944.
38. Wilkinson, D. E., et al. 2010. Establishment of the 1(st) world health organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int. J. Cancer 126:2969-2983.